TTC4 Antibody

What is TTC4 and what cellular functions does it perform?

TTC4 is a protein containing tetratricopeptide (TPR) repeats that mediates protein-protein interactions and chaperone activity. Research indicates that TTC4 serves several critical functions:

• Acts as a co-chaperone for HSP90AB1, facilitating proper protein folding and stabilization

• Promotes Sendai virus (SeV)-induced host cell innate immune responses, suggesting a role in antiviral defense mechanisms

• Inhibits inflammation and pyroptosis in sepsis-induced acute lung injury (ALI) models

• Interacts specifically with heat shock proteins 70 and 90 at defined amino acid regions

• Regulates mitochondrial function and integrity in macrophages during inflammatory responses

Importantly, clinical data has shown that TTC4 expression is significantly inhibited in patients with sepsis-induced ALI, with a negative correlation between serum TTC4 mRNA levels and serum IL-1β levels, highlighting its potential diagnostic value .

What types of TTC4 antibodies are available and how should researchers select the appropriate one?

Researchers can choose from several types of TTC4 antibodies, each with distinct characteristics suitable for different experimental approaches:

When selecting an antibody, researchers should consider:

• Experimental technique: Different antibodies show varying performance across techniques. For instance, ab181194 demonstrates exceptional sensitivity in Western blot (1:50000 dilution) , while TA365818 is primarily validated for immunohistochemistry .

• Species: If working with mouse or rat models, select antibodies with cross-reactivity to these species, such as Proteintech's 11878-1-AP .

• Specific application requirements: For protein interaction studies requiring immunoprecipitation, ab181194 would be preferable as it's validated for IP .

• Target epitope: For mechanistic studies examining specific protein domains, consider antibodies targeting different regions of TTC4 to avoid interference with protein-protein interactions.

What are the optimal conditions for using TTC4 antibodies in Western blotting?

Optimizing Western blot protocols for TTC4 detection requires careful consideration of multiple parameters:

Important considerations for troubleshooting:

• Non-specific bands: A validated user of Proteintech's 11878-1-AP reported an additional non-specific band below the expected 45 kDa band that persisted after knockdown verification .

• Signal intensity: If signal is weak despite using recommended dilutions, consider longer exposure times or more sensitive detection reagents.

• Sample integrity: Fresh lysates typically yield better results than repeatedly freeze-thawed samples.

How can TTC4 antibodies be optimized for immunohistochemistry applications?

Successful immunohistochemical detection of TTC4 requires careful optimization of multiple parameters:

For optimal results:

• Perform careful titration of primary antibody concentration for each new tissue type

• Include both positive and negative controls in each experiment

• Document lot-to-lot variations in antibody performance

• Consider double-staining with cell-type specific markers when working with heterogeneous tissues

What methodological considerations are essential when studying TTC4 protein-protein interactions?

Investigating TTC4 interactions with other proteins, particularly heat shock proteins, requires careful methodological approaches:

• Immunoprecipitation (IP) approaches:

  • Ab181194 has been validated for IP at 1:50 dilution in 293T cell lysate

  • Always include proper negative controls (e.g., non-specific IgG) to verify specific interactions

  • For co-IP experiments, consider using antibodies against both TTC4 and its potential interaction partners (e.g., HSP70) to confirm bidirectional pull-down

• Structural interaction analysis:

  • Research has shown that TTC4 protein interacts with HSP70 protein at specific regions:

    • Primary interaction at amino acids 283-286 of TTC4

    • TTC4 interacts with HSP70 primarily at amino acids 403-426, and secondarily at amino acids 473-475 or 530-604

  • Consider using deletion constructs targeting these specific regions to confirm interaction sites

• Confocal microscopy approaches:

  • Double immunofluorescence staining can reveal co-localization patterns

  • Research has demonstrated that TTC4 promotes HSP70 protein expression in in vitro models

  • Use appropriate controls to validate specificity of observed co-localization

• Proximity ligation assays (PLA):

  • Can provide higher specificity for detecting TTC4-HSP70/HSP90 interactions

  • Requires antibodies raised in different host species or using directly conjugated antibodies

• Functional validation:

  • Combining interaction studies with functional assays is essential

  • Research has shown that modulating HSP70 activity with agonists (TRC051384) or inhibitors (YK5) affects TTC4-mediated protection against pyroptosis

How can TTC4 antibodies be used to investigate sepsis-induced acute lung injury mechanisms?

Research highlights several methodological approaches using TTC4 antibodies to study sepsis-induced ALI:

• Expression analysis in clinical samples:

  • TTC4 mRNA levels are significantly inhibited in serum from patients with sepsis-induced ALI

  • Negative correlation exists between serum TTC4 mRNA levels and serum IL-1β levels

  • Receiver operating characteristic (ROC) curve analysis demonstrated diagnostic value of TTC4 levels in sepsis-induced ALI

• Animal model assessment:

  • Western blot analysis showed reduced TTC4 protein expression in lung tissue from mouse models of sepsis-induced ALI

  • Immunofluorescence and immunohistochemistry confirmed down-regulation of TTC4 expression in lung tissue

  • Sh-TTC4 virus introduction aggravated various parameters of lung injury:

    • Increased inflammatory cells in bronchoalveolar lavage fluid

    • Elevated neutrophils, lymphocytes, serum IgE and HDM-specific IgE levels

    • Enhanced levels of inflammatory cytokines

• Mechanistic pathway analysis:

  • TTC4 knockdown induced protein expressions of NLRP3 and Caspase-1 in both in vitro and in vivo models

  • TTC4 overexpression suppressed NLRP3 and Caspase-1 expression

  • HSP70 agonist (TRC051384) administration reversed the effects of TTC4 knockdown

These findings collectively demonstrate how TTC4 antibodies can be instrumental in elucidating the protective role of TTC4 in sepsis-induced ALI through HSP70-dependent mechanisms.

What role does TTC4 play in pyroptosis regulation and how can researchers investigate this mechanism?

TTC4 has emerged as an important negative regulator of pyroptosis, particularly in sepsis models. Researchers can investigate this mechanism using several approaches:

• Experimental design for studying TTC4 in pyroptosis:

  • Combine TTC4 overexpression or knockdown with assessment of key pyroptosis markers:

    • GSDMD (gasdermin D) - the executioner of pyroptosis

    • NLRP3 - a key inflammasome component

    • Caspase-1 - responsible for cleaving and activating GSDMD

• Functional assessment of pyroptosis:

  • Cell viability assays: Research showed TTC4 overexpression increased cell growth

  • LDH activity measurement: TTC4 overexpression decreased LDH release, indicating reduced cell death

  • Mitochondrial function assessment: TTC4 improved mitochondrial function as measured by:

    • Increased JC-1 disaggregation

    • Enhanced mitochondrial permeability transition (MPT) via calcein AM/CoCl2 assay

• Molecular pathway analysis:

  • Western blot analysis revealed TTC4 overexpression:

    • Induced HSP70 expression

    • Suppressed NLRP3 and Caspase-1 expression

  • Conversely, TTC4 knockdown:

    • Reduced HSP70 expression

    • Induced NLRP3 and Caspase-1 expression

• Intervention studies:

  • HSP70 agonist (TRC051384) reversed the effects of TTC4 knockdown by:

    • Inducing HSP70 protein expression

    • Suppressing NLRP3 and Caspase-1 expressions

    • Reducing inflammation in the sepsis mouse model

  • HSP70 inhibitor (YK5) counteracted the protective effects of TTC4 overexpression

These methodological approaches provide a comprehensive framework for researchers investigating TTC4's role in pyroptosis regulation, highlighting the central importance of the TTC4-HSP70 axis in this process.

How can researchers validate TTC4 antibody specificity across different experimental systems?

Ensuring antibody specificity is crucial for reliable TTC4 research. Recommended validation approaches include:

• Multi-technique validation:

  • Compare antibody performance across multiple techniques (WB, IHC, ICC/IF)

  • Consistent results across techniques strengthen confidence in specificity

  • Observed discrepancies may indicate epitope accessibility issues in different sample preparations

• Genetic validation approaches:

  • Knockdown/knockout controls: A customer review of Proteintech's 11878-1-AP mentioned validation "by knockdown at expected size"

  • Overexpression systems: Testing antibodies on samples overexpressing TTC4 should show increased signal intensity

  • CRISPR-Cas9 edited cell lines can provide definitive negative controls

• Cross-antibody validation:

  • Compare results using multiple antibodies targeting different TTC4 epitopes

  • Consistent results with different antibodies increase confidence in specificity

  • Consider using both monoclonal (e.g., ab181194/ab181195) and polyclonal (e.g., 11878-1-AP) antibodies

• Species cross-reactivity assessment:

  • When working with animal models, verify antibody performance in the specific species

  • Proteintech's 11878-1-AP shows reactivity with human, mouse, and rat samples

  • Consider sequence homology in the targeted epitope region when interpreting cross-species reactivity

• Technical controls:

  • Primary antibody omission: Controls for non-specific binding of secondary antibody

  • Isotype controls: Controls for non-specific binding of IgG

  • Absorption controls: Pre-incubation of antibody with immunizing peptide should abolish specific signal

What emerging applications exist for TTC4 antibodies in therapeutic antibody development research?

Recent advances in therapeutic antibody development methodologies can be applied to TTC4 research:

• Computational antibody design approaches:

  • Modern antibody discovery pipelines integrate physics- and AI-based methods to optimize both binding affinity and developability characteristics

  • These approaches could potentially be applied to develop highly specific anti-TTC4 therapeutic antibodies or to target the TTC4-HSP70 interaction

• Developability assessment:

  • Aggregation is a major challenge in antibody therapeutics

  • Computational methods for predicting antibody structure and aggregation propensity could be valuable for developing TTC4-targeting therapeutics

  • Recent research demonstrated successful computational design of antibodies with improved developability characteristics while maintaining binding properties

• TTC4 pathway modulation:

  • Given TTC4's protective role in sepsis-induced ALI , antibodies or small molecules that enhance TTC4 activity or the TTC4-HSP70 interaction could have therapeutic potential

  • The research demonstrated that activating the HSP70 signaling pathway in the context of TTC4 knockdown had protective effects

• Diagnostic applications:

  • The negative correlation between TTC4 levels and inflammatory markers suggests potential diagnostic applications

  • ROC curve analysis demonstrated diagnostic value of TTC4 levels in sepsis-induced ALI

  • Development of standardized immunoassays using TTC4 antibodies could facilitate clinical translation

• Engineering antibodies targeting TTC4-protein interactions:

  • Given the specific interaction sites identified between TTC4 and HSP70 (amino acids 283-286 of TTC4 and 403-426 of HSP70) , antibodies could be designed to specifically modulate these interactions

  • This approach would require sophisticated structural understanding and computational design methods similar to those described for other therapeutic antibodies

How can TTC4 antibodies be utilized in multi-parametric imaging studies of inflammatory processes?

Advanced imaging applications using TTC4 antibodies can provide deeper insights into inflammatory processes:

• Multiplex immunofluorescence approaches:

  • Combine TTC4 staining with markers of:

    • Cell types (macrophages, neutrophils, epithelial cells)

    • Pyroptosis (GSDMD, cleaved caspase-1)

    • Heat shock proteins (HSP70, HSP90)

  • This allows visualization of TTC4 expression patterns in specific cell populations and correlation with pyroptosis markers

• Live-cell imaging methodologies:

  • TTC4-fluorescent protein fusions combined with fluorescently-tagged HSP70/HSP90

  • Allows real-time visualization of protein dynamics and interactions

  • Could provide insights into the kinetics of TTC4-HSP70 interactions during inflammatory responses

• Super-resolution microscopy:

  • STED, PALM, or STORM techniques using TTC4 antibodies

  • Provides nanoscale resolution of TTC4 localization and its colocalization with interaction partners

  • Could reveal subcellular compartmentalization of TTC4-HSP70 interactions not visible with conventional microscopy

• Correlative light and electron microscopy (CLEM):

  • Combines immunofluorescence localization of TTC4 with ultrastructural analysis

  • Could provide insights into TTC4's relationship with mitochondria and other organelles during pyroptosis

  • Particularly relevant given TTC4's role in mitochondrial function

• Intravital imaging in animal models:

  • Using fluorescently-labeled TTC4 antibodies or reporter systems

  • Allows visualization of TTC4 dynamics in live animals during sepsis progression

  • Could provide valuable insights into the temporal and spatial regulation of TTC4 in vivo

What strategies can resolve common technical challenges when using TTC4 antibodies?

Researchers may encounter several challenges when working with TTC4 antibodies that can be addressed through methodical troubleshooting:

• Non-specific Western blot bands:

  • A verified user of Proteintech's 11878-1-AP reported "an additional non-specific band underneath" the expected 45 kDa band

  • Solutions:

    • Optimize antibody concentration following product-specific recommendations

    • Increase blocking time and stringency of washing steps

    • Consider using alternative antibodies with higher specificity

    • Include knockdown/knockout controls to differentiate specific from non-specific bands

• Weak or inconsistent immunohistochemistry signals:

  • Solutions:

    • Ensure appropriate antigen retrieval method (EDTA buffer pH 9 for Abcam antibodies , TE buffer pH 9.0 or citrate buffer pH 6.0 for Proteintech's antibody )

    • Optimize primary antibody concentration for each tissue type

    • Consider signal amplification systems for low-abundance targets

    • Use fresh tissue sections as prolonged storage can reduce antigenicity

• Variability in immunoprecipitation efficiency:

  • Solutions:

    • Optimize antibody-to-lysate ratio (ab181194 has been validated at 1:50 dilution )

    • Adjust lysis buffer composition to preserve protein-protein interactions

    • Consider crosslinking approaches for transient interactions

    • Pre-clear lysates to reduce non-specific binding

• Inconsistent results across different sample types:

  • Solutions:

    • Standardize sample preparation protocols

    • Adjust antibody concentrations based on expected TTC4 expression levels

    • Consider tissue/cell-specific optimizations of blocking and washing steps

    • Use internal controls to normalize for technical variations

• Difficulties in detecting TTC4-HSP70 interactions:

  • Solutions:

    • Use mild lysis conditions to preserve protein-protein interactions

    • Consider in situ approaches like proximity ligation assays

    • Use multiple antibodies targeting different epitopes to ensure accessibility

    • Include positive controls (known interaction partners) in co-IP experiments

How can researchers optimize experimental design when studying TTC4 in complex inflammatory models?

Studying TTC4 in complex inflammatory models requires careful experimental design:

• Model selection considerations:

  • In vitro models: Research has used macrophage cell lines treated with inflammatory stimuli

  • In vivo models: Mouse models of sepsis-induced ALI have been validated

  • Clinical samples: Serum samples from sepsis-induced ALI patients show decreased TTC4 levels

• Temporal analysis strategy:

  • Include multiple time points to capture dynamic changes in TTC4 expression

  • Correlate TTC4 expression with disease progression markers

  • Design intervention studies (e.g., with HSP70 agonists) at appropriate disease stages

• Cell-type specific analysis:

  • Use cell sorting or single-cell approaches to isolate specific cell populations

  • Combine with TTC4 expression analysis to identify cell types with key regulatory roles

  • Consider cell-type specific knockdown/overexpression approaches

• Comprehensive biomarker assessment:

  • Correlate TTC4 expression with:

    • Inflammatory cytokines (IL-1β, IL-6, INF-γ, TNF-α)

    • Pyroptosis markers (GSDMD, NLRP3, Caspase-1)

    • Clinical parameters in patient samples

• Intervention design:

  • Consider both genetic approaches (TTC4 knockdown/overexpression) and pharmacological interventions (HSP70 agonists/inhibitors)

  • Include appropriate controls for each intervention

  • Assess multiple endpoints to capture the full spectrum of TTC4's effects

• Statistical considerations:

  • Determine appropriate sample sizes based on expected effect sizes

  • Account for heterogeneity in complex disease models

  • Consider multivariate analysis approaches to identify key correlations

By implementing these experimental design strategies, researchers can more effectively investigate TTC4's complex roles in inflammatory processes and potentially identify new therapeutic approaches for conditions like sepsis-induced ALI.